Overlooked Alpha

Overlooked Alpha

Share this post

Overlooked Alpha
Overlooked Alpha
50% Gains Are Possible For This $7B Medtech Stock

50% Gains Are Possible For This $7B Medtech Stock

A leader in diagnostic testing looks attractive after sell-off

Joe | 3MB
and
Overlooked Alpha
Oct 22, 2023
∙ Paid
6

Share this post

Overlooked Alpha
Overlooked Alpha
50% Gains Are Possible For This $7B Medtech Stock
Share

Highlights:

  • This business exploded during the pandemic thanks to COVID testing revenue. But the business was performing well before then.

  • With COVID revenue bottoming, strength in a historically attractive business is about to shine through.

  • We think the stock has 50% upside in a conservative scenario, making it more than worth the risk near the lows.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Joe Marwood
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share